Comparing Two Types of Sedation to Gynaecological Patients

NCT ID: NCT01412632

Last Updated: 2014-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

153 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary endpoint is to investigate the difference in pain between patients who receive deep sedation with spontaneous breathing versus patients who receive general anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigate the difference between two types of anesthesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transcervical Resection of Endometrium Transcervical Resection of Fibroids Transcervical Resection of Polyp

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

General vs deep sedation

General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest

Group Type EXPERIMENTAL

Remifentanil, propofol and citanest

Intervention Type DRUG

iv remifentanil iv propofol im citanest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remifentanil, propofol and citanest

iv remifentanil iv propofol im citanest

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years
* females
* are having a TCRE, TCRF or TCRP
* speak and understand Danish
* no mental problems

Exclusion Criteria

* \<18 years old
* don“t speak or understand Danish
* mental problems
* Lung problems
* BMI \>40
* Big fibroma: \>3x3 cm
* abuser
* Allergy towards i Propofol, Remifentanil and/or Citanest
* pregnant
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regionshospitalet Horsens

OTHER

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Igor Filipovski

Role: PRINCIPAL_INVESTIGATOR

Regionshospital Horsens

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Regionshospitalet Horsens

Horsens, Region Midt, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-023843-13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.